Molecular Medicine Research Institute (MMRI)

mmrx.org

The Molecular Medicine Research Institute (MMRI) is committed to translating scientific laboratory findings into direct patient care. Since 1995, MMRI has been exploring the molecular basis of chronic diseases and bridging the gap between science and medical practice through a unique two-part niche program.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

news image

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

news image

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More

NUCLEUS BIOLOGICS UNVEILS WORLD'S FIRST ONLINE PORTAL FOR INSTANTANEOUS CUSTOM CGMP CELL CULTURE MEDIA CONFIGURATION

Nucleus Biologics | May 27, 2020

news image

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™, an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000 liters.Media is a critical component in the production of cell therapies. During development, companies iteratively test multiple formulation...

Read More

CELL AND GENE THERAPY

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

news image

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More
news image

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More
news image

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More
news image

NUCLEUS BIOLOGICS UNVEILS WORLD'S FIRST ONLINE PORTAL FOR INSTANTANEOUS CUSTOM CGMP CELL CULTURE MEDIA CONFIGURATION

Nucleus Biologics | May 27, 2020

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™, an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000 liters.Media is a critical component in the production of cell therapies. During development, companies iteratively test multiple formulation...

Read More
news image

CELL AND GENE THERAPY

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More